Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.35 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244991 | 1.00 | CTSL (0.40) | CTSLRIPK1CTSSCTSKTSHR | |
| SCHEMBL25469179 | 0.84 | RIPK1 (0.46) | RIPK1CTSSCTSKTSHRMAN2A1 | |
| SCHEMBL26606649 | 0.84 | RIPK1 (0.46) | RIPK1CTSSCTSKTSHRMAN2A1 | |
| SCHEMBL20325561 | 0.83 | TRPV3 (0.43) | TSHRTRPV3 | |
| SCHEMBL22308451 | 0.83 | RIPK1 (0.44) | CTSLRIPK1CTSSCTSKTSHR | |
| SCHEMBL24361064 | 0.83 | RIPK1 (0.44) | CTSLRIPK1CTSSCTSKTSHR | |
| SCHEMBL21501094 | 0.81 | TRPV3 (0.35) | CTSLRIPK1CTSSCTSKTSHR | |
| SCHEMBL23460720 | 0.81 | RIPK1 (0.49) | RIPK1TSHR | |
| SCHEMBL23460721 | 0.81 | RIPK1 (0.49) | RIPK1TSHR | |
| SCHEMBL30457124 | 0.81 | RIPK1 (0.49) | RIPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | CTSL 160/4885RIPK1 4729/4885CTSS 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.